Drug Profile
Camoteskimab - Apollo Therapeutics
Alternative Names: AEVI-007; AVTX-007; CERC-007; MEDI 2338Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer Apollo Therapeutics; Avalo Therapeutics; MedImmune
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Interleukin 18 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Adult-onset Still's disease
- Discontinued Chronic obstructive pulmonary disease; Multiple myeloma
Most Recent Events
- 23 Aug 2023 Apollo Therapeutics terminates a phase I/II trial in Adult-onset Still's disease in Belgium, Poland, Ukraine, USA (IV) due to sponsor discretion (NCT04752371)
- 04 Nov 2022 Avalo Therapeutics enters into an agreement with ES Therapeutics to sell its net economic rights to future payments of previously out-licensed assets including camoteskimab
- 01 Aug 2022 Camoteskimab licensed to Apollo Therapeutics worldwide for the treatment of Adult onset stills disease and Inflammation